SCHEMBL173117

SCHEMBL173117

COc1cc(/C=C/C(=O)N2CCC=CC2=O)cc(OC)c1OCCNC(=O)OC(C)(C)C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.66
TP53 P04637 3/20 0.66
SMN1; SMN2 Q16637 2/20 0.66
MAPT P10636 2/20 0.66
HSD17B10 Q99714 2/20 0.66
LMNA P02545 2/20 0.66
CYP1A2 P05177 1/20 0.66
HIF1A Q16665 1/20 0.66
PSMB11 A5LHX3 1/20 0.66
PSMA7 O14818 1/20 0.66
NPC1 O15118 1/20 0.66
FOXO3 O43524 1/20 0.66
MITF O75030 1/20 0.66
CYP3A4 P08684 1/20 0.66
PSMB1 P20618 1/20 0.66
PSMA1 P25786 1/20 0.66
PSMA2 P25787 1/20 0.66
PSMA3 P25788 1/20 0.66
PSMA4 P25789 1/20 0.66
PSMB8 P28062 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25681948 0.96 ALDH1A1 (0.63) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL25681916 0.96 ALDH1A1 (0.63) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL25681985 0.96 ALDH1A1 (0.63) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL30496625 0.94 ALDH1A1 (0.63) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL173085 0.86 ALDH1A1 (0.75) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL25681875 0.84 ALDH1A1 (0.72) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL25682003 0.84 ALDH1A1 (0.69) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL25681999 0.84 ALDH1A1 (0.69) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL15444241 0.84 ALDH1A1 (0.66) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL25240648 0.84 ALDH1A1 (0.68) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130237539-A1 Compounds and Compositions for Treating Cancer THE GENERAL HOSPITAL CORPORATION (US) 2013-09-12 US disclosed
US-20130203757-A1 Compounds And Compositions For Treating Cancer THE GENERAL HOSPITAL CORPORATION (US) 2013-08-08 US disclosed
US-8349832-B2 Compounds and compositions for treating cancer Canthera Therapeutics (US) 2013-01-08 US disclosed
US-8318737-B2 Compounds and compositions for treating cancer CANTHERA THERAPEUTICS INC. (US) 2012-11-27 US disclosed
US-20120059004-A1 Compounds And Compositions For Treating Cancer CANTHERA THERAPEUTICS, INC. (US) 2012-03-08 US disclosed
US-20110053938-A1 Compounds and Compositions For Treating Cancer CANTHERA THERAPEUTICS, INC. (US) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059004-A1 Compounds And Compositions For Treating Cancer NQO1, HCCS, TXNRD2 ALDH1A1 503/4885TP53 7/4885SMN1; SMN2 1285/4885
US-20130203757-A1 Compounds And Compositions For Treating Cancer NQO1, HCCS, TXNRD2 ALDH1A1 503/4885TP53 7/4885SMN1; SMN2 1285/4885
US-20110053938-A1 Compounds and Compositions For Treating Cancer NQO1, HCCS, TXNRD2 ALDH1A1 503/4885TP53 7/4885SMN1; SMN2 1285/4885
US-20130237539-A1 Compounds and Compositions for Treating Cancer NQO1, HCCS, TXNRD2 ALDH1A1 503/4885TP53 7/4885SMN1; SMN2 1285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.